Project Grant R01AI196565
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Massachusetts Medical School a Project Grant totaling $832,076 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 8, 2025, with a completion date of July 31, 2030. This research initiative focuses on characterizing protective CD8 T cell responses to Mycobacterium tuberculosis (MTB) infection, with the ultimate objective of informing...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded University of Massachusetts Medical School a Project Grant of $139,968 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period September 30, 2025, through May 31, 2028. The award funds research investigating the relationship between genetic variants, transcriptional responses, and Mycobacterium tuberculosis (MTB) infection outcomes in macrophages derived from...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Tufts University School of Medicine a $156,080 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct fundamental research elucidating how innate immune cells modulate Mycobacterium tuberculosis (MTB) stress response and replication heterogeneity. The research project, which commenced January 29, 2026 and concludes August 15, 2028, investigates the...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Massachusetts a Project Grant of $224,943 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct fundamental research on cell wall carbohydrate recycling mechanisms in Mycobacterium tuberculosis. The award, effective September 18, 2025, through August 31, 2027, supports investigator-initiated biomedical research aimed at identifying and...
- Federal Grant Award Summary Boston University Medical Campus received a $245,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 9, 2026, with a completion date of January 31, 2028. The award funds research into the mechanisms of alternative macrophage activation in pulmonary tuberculosis, utilizing a genetic mouse model of chronic TB to investigate the phenotypes and...
- Federal Grant Award Summary Award Overview The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant totaling $756,714 to The Regents of the University of California, Berkeley, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, effective April 1, 2026, through March 31, 2031, supports fundamental research investigating the mechanisms by which Mycobacterium tuberculosis (MTB) evades and suppresses host immune responses. Research...
- Federal Grant Award Summary The University of Maryland, College Park received a $234,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 26, 2026, with completion targeted for April 30, 2028. This research grant funds a comprehensive investigation into phagosomal membrane repair mechanisms during Mycobacterium tuberculosis (MTB) infection in human macrophages. The project...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $141,712 to the University of California, Irvine on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a 24-month project concluding January 31, 2028. This Project Grant funds research to characterize a novel histidine phosphotransfer system in Mycobacterium tuberculosis (MTB), specifically investigating how the virulence-associated dikinase...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Southern Mississippi $750,000 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 20, 2025, with a completion date of August 31, 2029. This Project Grant supports investigator-initiated research aimed at elucidating the role of extracellular polyphosphate in Mycobacterium tuberculosis (MTB) antibiotic tolerance, with particular focus on how the...
- Federal Grant Award Summary Award Details: The National Institute of Allergy and Infectious Diseases (NIAID) awarded Washington University a $151,040 Project Grant (CFDA 93.855 – Allergy and Infectious Diseases Research) on December 23, 2025, with a completion date of June 30, 2028. The award supports research conducted at the university's Office of Sponsored Research Services in Missouri. Research Scope: This project investigates the mechanisms of sigma-factor-dependent transcriptional...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Massachusetts a $797,682 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective July 1, 2026, through June 30, 2031. This award funds research focused on developing chemical strategies to investigate mycomembrane remodeling and host interactions in Mycobacterium tuberculosis, the causative agent of tuberculosis. The research addresses critical knowledge gaps regarding how the mycobacterial outer mycomembrane functions as a permeability barrier and virulence factor. The project deliverables include the development and application of novel chemical tools—specifically clickable probes, fluorescence resonance energy transfer (FRET) probes, and photocrosslinking probes—to label and study mycomembrane components including glycans and lipids that are not directly genetically encoded. The research comprises two primary aims designed to advance understanding of tuberculosis pathogenesis and identify therapeutic vulnerabilities. Aim 1 focuses on using clickable and FRET probes to elucidate mechanisms and vulnerabilities associated with stress-triggered mycomembrane turnover. Aim 2 employs clickable and photocrosslinking probes to determine the mechanisms by which mycomembrane components interact with and manipulate host cells. Upon successful completion, these chemical strategies are expected to enable molecular-level mechanistic investigations of mycomembrane chemistry and biology, with anticipated benefits extending to the broader research community working on infectious disease diagnostics and therapeutics.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $797.7k | 6/30/26 |